

Treatment of Left Main Coronary Artery Disease in Patients with and without Diabetes by Bypass Graft Surgery Versus Percutaneous Coronary Intervention: The EXCEL Trial

Short title: LMCAD Revascularization with Diabetes

Milan Milojevic, MD, MSc^a, Patrick W. Serruys, MD, PhD^b, Joseph F. Sabik III, MD^c, David E. Kandzari, MD^d, Erick Schampaert, MD^e, Ad J. van Boven, MD, PhD^f, Ferenc Horkay, MD, PhD, DSc^g, Imre Ungi, MD, PhD^h, Samer Mansour, MDⁱ, Adrian P. Banning, MD^j, David P. Taggart, MD, PhD^k, Manel Sabaté, MD, PhD^k, Anthony H. Gershlick, MBBS, FRCP^l, Andrzej Bochenek, MD, PhD^m, Jose Pomar, MD, PhD^k, Nicholas J. Lembo, MDⁿ, Nicolas Noiseux, MDⁱ, John D. Puskas, MD^o, Aaron Crowley, MA^p, Ioanna Kosmidou, MD, PhD^{n,p}, Roxana Mehran, MD^{p,q}, Ori Ben-Yehuda, MD^{n,p}, Philippe G  n  reux, MD^{e,p,r}, Stuart J. Pocock, PhD^s, Charles A. Simonton, MD^t, Gregg W. Stone, MD^{n,p}, Arie Pieter Kappetein, MD, PhD^a

From ^aErasmus Medical Center, Rotterdam, The Netherlands; ^bImperial College of Science, Technology and Medicine, London, United Kingdom; ^cDepartment of Surgery, UH Cleveland Medical Center, Ohio; ^dPiedmont Heart Institute, Atlanta, Georgia; ^eH  pital du Sacre  -Coeur de Montr  al, Montreal, Quebec, Canada; ^fMedical Center Leeuwarden, Leeuwarden, The Netherlands; ^gSemmelweis University, Budapest, Hungary; ^hUniversity of Szeged, Szeged, Hungary; ⁱCentre Hospitalier de l'Universit   de Montr  al, Montreal, Quebec, Canada; ^jJohn Radcliffe Hospital, Oxford, UK; ^kHospital Clinic, Barcelona, Spain; ^lGlenfield Hospital, Leicester, United Kingdom; ^mAmerican Heart of Poland, Katowice, Poland; ⁿNew York-Presbyterian Hospital/Columbia University Medical Center, New York, New York; ^oMount Sinai Heart at Mount Sinai Saint Luke's, New York, New York; ^pClinical Trials Center, Cardiovascular Research Foundation, New York, New York; ^qThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; ^rGagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey; ^sLondon School of Hygiene and Tropical Medicine, London, United Kingdom; ^tAbbott Vascular, Santa Clara, California, USA;

Disclosures: Patrick W. Serruys: Consultant – Abbott, Biosensors, Medtronic, Micell Technologies, QualiMed, SINOMED, St. Jude Medical, Stentys, Svelte, Philips/Volcano, Xeltis. Joseph F. Sabik III: Consultant - Medtronic, Edwards, and Sorin. Advisory board - Medtronic Cardiac Surgery. David E. Kandzari: Consulting fees - Medtronic and Boston Scientific; research support - Medtronic, Abbott Vascular, Boston Scientific, Biotronik, and Medinol. Erick Schampaert: Consultant and/or speaker – Abbott Vascular, Boston Scientific, Philips Medical. Adrian P. Banning: Institutional sponsorship for a fellowship from Boston Scientific and lecture fees from Boston Medtronic and Abbott Vascular. Partially funded by the NHS Oxford NIHR Biomedical Research Centre. Nicholas J. Lembo: Consultant and speakers bureau – Abbott Vascular, Boston Scientific, Medtronic. Roxana Mehran: Institutional research grant support -

Eli Lilly/Daiichi-Sankyo, Inc., Bristol-Myers Squibb, AstraZeneca, The Medicines Company, OrbusNeich, Bayer, CSL Behring, Abbott Laboratories, Watermark Research Partners, Novartis Pharmaceuticals, Medtronic, AUM Cardiovascular, Inc., Beth Israel Deaconess Medical Center; executive committee - Janssen Pharmaceuticals, Osprey Medical Inc.; data safety monitoring board - Watermark Research Partners; consulting - Medscape, The Medicines Company, Boston Scientific, Merck & Company, Cardiovascular Systems, Inc. (CSI); Sanofi USA, LLC, Shanghai BraccoSine Pharmaceutical Corp.; AstraZeneca; equity - Claret Medical Inc., Elixir Medical Corporation. Philippe G  n  reux: Speaker's fees - Abbott Vascular, Edwards Lifescience, Medtronic, Tryton Medical Inc., Cardinal Health, and Cardiovascular Systems Inc., consulting fees - Abbott Vascular, Boston Scientific, Cardiovascular Systems Inc., and Pi-Cardia; institutional research grant - Boston Scientific. Equity - SIG.NUM, SoundBite Medical Solutions Inc., Saranas, and Pi-Cardia. Stuart Pocock: Consultant - Abbott Vascular. Charles A. Simonton: Employee – Abbott Vascular. Gregg W. Stone: Employer, Columbia University, receives royalties for sale of the MitraClip. Arie Pieter Kappetein: Employee – Medtronic. The rest of the authors: None.

Word count: 2726

Twitter: @kandzari, @Drroxmehran; @philgenereux, @AKappetein, @DrChuckSimonton, @GreggWStone

Corresponding author:

Arie Pieter Kappetein, MD, PhD
Department of Cardio-Thoracic Surgery
Erasmus University Medical Center
P.O. Box 2040
3000 CA Rotterdam
The Netherlands
Tel.: +31 10 70 32150; Fax.: +31 10 70 33993
E-mail: a.kappetein@erasmusmc.nl

ABSTRACT

Background: The randomized EXCEL trial reported a similar rate of the 3-year composite primary endpoint of death, myocardial infarction (MI), or stroke in patients with left main coronary artery disease (LMCAD) and site-assessed low or intermediate SYNTAX scores treated with percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG). Whether these results are consistent in high-risk patients with diabetes, who have fared relatively better with CABG in most prior trials, is unknown.

Objectives: In this prespecified subgroup analysis from the EXCEL trial we sought to examine the effect of diabetes in patients with LMCAD treated with PCI versus CABG.

Methods: Patients (N=1905) with LMCAD and site-assessed low or intermediate CAD complexity (SYNTAX scores ≤ 32) were randomized 1:1 to PCI with everolimus-eluting stents (EES) versus CABG, stratified by the presence of diabetes. The primary endpoint was the rate of a composite of all-cause death, stroke, or MI at 3 years. Outcomes were examined in patients with (n=554) and without (n=1350) diabetes.

Results: The 3-year composite primary endpoint was significantly higher in diabetic compared with non-diabetic patients (20.0% versus 12.9%, $p < 0.001$). The rate of the 3-year primary endpoint was similar after treatment with PCI and CABG in diabetic patients (20.7% versus 19.3%, respectively; hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.71–1.50, $p = 0.87$) and non-diabetic patients (12.9% versus 12.9%, respectively; HR 0.98, 95% CI 0.73–1.32, $p = 0.89$). All-cause death at 3 years occurred in 13.6% PCI and 9.0% CABG patients ($p = 0.046$), although no significant interaction was present between diabetic status and treatment for all-cause death ($p = 0.22$) or other endpoints including the 3-year primary endpoint ($p = 0.82$) or the

major secondary endpoints of death, MI, or stroke at 30 days ($p=0.61$) or death, MI, stroke, or ischemia-driven revascularization at 3 years ($p=0.65$).

Conclusions: In the EXCEL trial, the relative 30-day and 3-year outcomes of PCI with EES versus CABG were consistent in diabetic and non-diabetic patients with LMCAD and site-assessed low or intermediate SYNTAX scores.

Keywords: Percutaneous coronary intervention, coronary artery bypass grafting, left main disease, diabetes, SYNTAX score.

CONDENSED ABSTRACT

Diabetes mellitus is a significant determinant of the long-term survival after myocardial revascularization. This prespecified subgroup analysis from the EXCEL trial evaluates the safety and efficacy of percutaneous coronary intervention (PCI) using everolimus-eluting stents (EES) compared with coronary artery bypass surgery (CABG) among 1905 patients with left main disease according to diabetes status. Over 3 years of follow-up there were no significant differences in the primary composite endpoint of all-cause death, stroke, or myocardial infarction between PCI and CABG in both diabetic (20.7% versus 19.3%, $p=0.87$, respectively) and non-diabetic patients (12.9% versus 12.9%, $p=0.89$, respectively) ($p_{\text{interaction}}=0.82$).

Abbreviations and Acronyms

BIMA = bilateral internal mammary artery

CABG = coronary artery bypass grafting

CAD = coronary artery disease

DES = drug-eluting stents

DM = diabetes mellitus

IDR = ischemia-driven revascularization

LM = left main coronary artery

MI = myocardial infarction

PCI = percutaneous coronary intervention

SIMA = single internal mammary artery

The number of people with diabetes mellitus is increasing, having risen from 108 million in 1980 to 422 million in 2014 (1). Patients with diabetes are at an increased risk for systemic atherosclerosis and advanced coronary artery disease (CAD), and diabetes is a predictor of adverse events after both coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) (2, 3). In patients with diabetes and complex anatomic disease, CABG has been associated with lower mortality rates compared to PCI (3-5). As a result, CABG has been recommended as the standard of care for patients with diabetes and complex CAD including left main (LM) disease (6); however, in a recent pooled analysis of 3 randomized trials (2 of which were performed more than a decade ago), patients with diabetes and low or intermediate anatomic complexity as signified by a SYNTAX score of ≤ 32 had similar 5-year rates after PCI and CABG of all-cause death, cardiac death, and the composite of death, myocardial infarction (MI), or stroke (7). Conversely, patients with high (≥ 33) SYNTAX scores had significantly higher adverse event rates with PCI compared with CABG. Since the performance of these trials, both PCI technology and technique, as well as surgical methods and outcomes, have continued to improve. The extent to which diabetes thus influences outcomes after contemporary revascularization strategies in patients with LMCAD is unknown.

The Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial was a large-scale study in which selected patients with LMCAD were randomized to PCI with everolimus-eluting stents (EES) versus CABG (8). Acknowledging the importance of diabetes, randomization was stratified by the presence of this variable to ensure balance baseline in the diabetic and non-diabetic strata. The present report describes the pre-specified subgroup analysis examining the impact of diabetes on 30-day and 3-year outcomes after PCI versus CABG in patients with LMCAD.

METHODS

Study design. The protocol, patient eligibility criteria and methods of the EXCEL trial have been reported previously (9). EXCEL was a prospective, multinational, unblinded randomized trial in which 1905 patients with *de novo* LMCAD and site-assessed SYNTAX scores ≤ 32 in whom equipoise was present for transcatheter versus surgical revascularization were randomly (1:1) assigned to undergo PCI with cobalt–chromium fluoropolymer-based EES (Abbott Vascular, Santa Clara, California) or CABG. Patients were assessed for eligibility at each participating site by a heart team that consisted of (at least) an interventional cardiologist and a cardiac surgeon (10). Randomization was stratified according to the presence of diabetes and site. The trial was approved by the investigational review board or ethics committee at each participating center. All patients provided written informed consent before enrolment. The trial was funded by Abbott Vascular (Santa Clara, California) but led by a broad academic group with equal representation of interventional cardiologists and cardiac surgeons (8,9). The trial is registered at clinicaltrials.gov, identifier NCT01205776.

Endpoints and definitions. The primary endpoint was the 3-year rate of all-cause mortality, stroke, or MI. Major powered secondary outcomes included this endpoint at 30 days and the composite rate of death, stroke, MI, or ischemia-driven revascularization (IDR) at 3 years. Other secondary endpoints included the components of the primary and secondary endpoints as well as revascularization, stent thrombosis, symptomatic graft stenosis or occlusion, and a pre-specified composite of periprocedural major adverse events.

The definitions of these outcome measures have been previously described in detail (8,9). In brief, stroke was defined as a focal neurological deficit of central origin lasting >24 hours,

confirmed by a neurologist and imaging. Post-procedure MI was defined as the rise within 72 hours after PCI or CABG of CK-MB to $>10\times$ the upper reference limit (URL), or $>5\times$ URL plus new pathological Q waves in at least 2 contiguous leads or new persistent non-rate related left bundle branch block, or angiographically documented graft or native coronary artery occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Spontaneous MI was defined as the occurrence >72 hours after PCI or CABG of a rise and fall of cardiac biomarkers (CK-MB or troponin) $>1\times$ URL plus ECG changes indicative of new ischemia, or development of pathological Q waves in ≥ 2 contiguous ECG leads, or angiographically documented graft or native coronary artery occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Revascularization events were classified as either ischemia-driven or non-ischemia-driven by pre-specified criteria (9). An independent clinical events committee adjudicated all primary and secondary endpoints with source document verification.

Patients with diabetes at baseline were categorized according to treatment as (i) insulin-treated (with or without oral hypoglycemic agents); (ii) oral hypoglycemic agent-treated without insulin; and (iii) non-pharmacologic therapy only including dietary modification, exercise, and weight reduction. Using this classification, the following diabetic subgroups were defined and analyzed in the present study: (i) insulin-treated patients with or without oral hypoglycemic agents and (ii) non-insulin-treated patients (as only a small number of patients were treated without medications).

Statistical analysis. Subgroup analysis according to diabetes status with formal interaction testing was pre-specified in the trial protocol, although no formal statistical hypothesis was defined *a priori*. All analyses were performed with data from the time of randomization in the intention-to-treat population, which included all patients according to the group to which they were randomly assigned, regardless of the treatment received. Data are summarized using descriptive statistics, presented as proportions (% , count/sample size) or mean \pm standard deviation. Continuous variables were compared using the Student *t* test; differences in categorical variables were assessed with the χ^2 test or Fisher exact test, as appropriate. Event rates were based on Kaplan–Meier estimates in time-to-first-event analyses and were compared by the log-rank test. Multivariable predictors of 3-year outcomes were identified using step-wise selection with a significance level of <0.10 for entry and exit in a logistic regression model. P values for interaction were generated by logistic regression χ^2 test. Analyses according to SYNTAX score tertiles (low 0-22, intermediate 23-32, high ≥ 33) were performed using 3-year Kaplan–Meier event estimates. All analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, North Carolina).

RESULTS

Baseline and procedural characteristics. Baseline diabetes status was known in 1904 of 1905 randomized patients. Diabetes was present in 554/1904 patients (29.1%); 147 patients were treated with insulin, 358 were treated with oral hypoglycemic agents without insulin, and 49 were treated with non-pharmacologic measures. Patients with diabetes had a significantly greater number of comorbidities compared to non-diabetic patients, including hypertension, hyperlipidemia, anemia, renal insufficiency, peripheral vascular disease, congestive heart failure,

prior stroke, and a higher STS score, although were less likely to be current smokers (Table 1).

By core laboratory analysis, diabetic patients also had a higher SYNTAX score, more frequently had diffuse or small vessel disease, and a greater number of treated lesions.

As shown in Table 2, bilateral internal mammary artery (BIMA) grafting was performed significantly less frequently in patients with compared to patients without diabetes (19.6% versus 32.4%, $p<0.001$). Off-pump CABG technique, total bypass time, and the number of grafts did not differ between groups. Mean PCI duration was significantly longer in diabetic than in non-diabetic patients. There were no significant differences between the groups in other PCI procedural aspects. At hospital discharge, no differences in the administration of antiplatelet agents, statins, and beta-blockers were found between diabetic and non-diabetic patients after both PCI and CABG (Table 2). Medication use during follow-up is presented in Supplemental Table 1.

Thirty-day outcomes. As shown in Table 3, the 30-day rates of major adverse events were not significantly different in diabetic compared with non-diabetic patients; however, in both diabetic and non-diabetic patients, the 30-day rate of the composite endpoint of death, stroke, or MI was higher after CABG than after PCI. The difference in outcome was driven mainly by higher rates of stroke and MI after CABG, while rates of all-cause death and ischemia-driven revascularization were similar between CABG and PCI. Major adverse events were also higher after CABG than PCI in both diabetic and non-diabetic patients. Acute renal failure within 30 days occurred more commonly in patients with compared to those without diabetes (2.7% versus 1.1%, $p=0.01$), and was more frequent after revascularization with CABG compared with PCI both in patients with (4.1% versus 1.4%; $p=0.005$) and without (1.9% versus 0.3%, $p=0.05$) diabetes ($p_{\text{interaction}}=0.44$) (Supplemental Table 2). Among CABG patients, sternal wound

dehiscence occurred in 0.4% versus 1.2% of diabetic and non-diabetic patients respectively ($p=0.26$). Furthermore, sternal dehiscence did not occur more often after the use of BIMA compared to single internal mammary artery (SIMA) technique (0% versus 0.5%, $p=0.68$). There were no significant interactions between diabetes status and treatment for any of the 30-day study endpoints.

Three-year outcomes. Clinical outcomes according to diabetes status and treatment group are shown in Table 4 and Figure 1. Compared to non-diabetic patients, diabetic patients had higher 3-year rates of the composite primary endpoint, including higher rates of all-cause death, cardiovascular death, MI, and IDR. The rates of the 3-year composite primary endpoint of death, stroke, or MI, or the secondary composite endpoint of death, stroke, MI, or IDR were not significantly different between CABG and PCI in both the non-diabetic and diabetic cohorts. The 3-year rate of all-cause death was significantly higher after PCI compared with CABG in diabetic patients (13.6% versus 8.0%, $p=0.046$) but not in non-diabetic patients (5.5% versus 5.0%, $p=0.71$). IDR rates were lower after CABG compared with PCI in both diabetic and non-diabetic patients, whereas graft occlusion or stent thrombosis rates were lower after PCI compared with CABG. There were no significant interactions between diabetes status and treatment for any of the 3-year study endpoints, including mortality.

Impact of insulin treatment. Among diabetic patients, insulin use was associated with greater 3-year rates of MI and IDR (Supplemental Table 3). The rate of the 3-year primary composite endpoint of death, stroke, or MI was similar after PCI and CABG in both insulin-treated and non-insulin-treated diabetics (Figure 2). There were no significant interactions between insulin use, revascularization modality, and 3-year outcomes among diabetic patients (Supplemental Table 3).

SYNTAX score subgroups. Analysis according to site-reported coronary complexity showed a step-wise increase in 3-year event rates with intermediate compared to low SYNTAX scores in diabetic patients, but similar event rates in non-diabetic patients (Figure 3 and Supplemental Table 4). In patients with diabetes and low SYNTAX scores (0-22), no significant 3-year event rate differences were observed between CABG and PCI, except for IDR (7.8% versus 17.0%, $p=0.02$, respectively); however, 3-year mortality was lower after CABG compared with PCI among the 237 diabetic patients with intermediate SYNTAX scores (9.6% versus 19.6%, $p=0.04$). However, the interaction between low versus intermediate site-assessed SYNTAX score and revascularization modality for 3-year death in diabetic patients was not significant ($p=0.32$). Among non-diabetic patients, rates of adverse events were not significantly different after PCI and CABG irrespective of SYNTAX scores. The results according to core lab adjudication were similar to those from the site-reported analysis (Supplemental Table 5 and Supplemental Figure 1).

Multivariable analysis. As shown in Supplemental Table 6 and Supplemental Table 7, diabetes was an independent predictor for the composite endpoint of death, stroke, or MI after both CABG (HR 1.55, 95% CI 1.04-2.31; $p=0.03$) and PCI (HR 1.53, 95% CI 1.04-2.26; $p=0.03$). Diabetes was also an independent predictor of stroke after CABG and all-cause death after PCI.

DISCUSSION

The present pre-specified EXCEL substudy examined the impact of diabetes on clinical outcomes after PCI with EES versus CABG in patients with LMCAD and site-assessed low or intermediate SYNTAX scores. Compared to non-diabetic patients, diabetic patients with

LMCAD were at a nearly two-fold higher risk for all-cause death, stroke, or MI 3 years. There was no significant difference in the 3-year composite primary endpoint of death, stroke, or MI or the powered 3-year secondary endpoint of death, stroke, MI, or IDR after PCI or CABG either in the diabetic or non-diabetic strata. Thirty-day adverse events were significantly less after PCI compared with CABG both in diabetic and non-diabetic patients. Conversely, all-cause mortality at 3 years was greater after PCI compared with CABG among diabetic patients with higher site-assessed SYNTAX scores, although the interaction between site-assessed SYNTAX score and revascularization modality for 3-year death in diabetic patients was not significant. IDR at 3 years was higher with PCI whereas graft failure or thrombosis rates were higher after CABG, both irrespective of diabetic status.

Our findings confirm that diabetes is a critical determinant of long-term outcomes after myocardial revascularization (3, 4). Currently, no specific recommendation exists concerning the optimal revascularization strategy in diabetic patients with LMCAD (6). Given the clinical and anatomic complexity that is frequently present in this high-risk subgroup, the selection between CABG and PCI in diabetic patients requires careful consideration. Large registry data show a substantial increase in the number of patients with diabetes and LMCAD undergoing PCI over the last 20 years, although outcomes data are scarce (11). Prior to the present report, comparative effectiveness data for PCI with DES versus CABG in diabetic patients were limited to small subgroup analyses from clinical trials. In a pooled analysis of individual patient data from the PRECOMBAT and the SYNTAX trials, Cavalcante et al. (12) found no difference in the occurrence of major adverse events between CABG and PCI with first-generation DES in LM patients with or without diabetes at 5-year follow-up. The present results in which second-generation EES and contemporary CABG techniques were evaluated are consistent with these

findings and indicate that both revascularization strategies result in comparable rates of major adverse events at 3 years.

Although PCI resulted in substantially fewer major adverse events at 30 days in both diabetic and non-diabetic patients, an important consideration affecting the selection of revascularization procedure is long-term survival. In this regard, a large propensity-matched analysis of 4048 patient-pairs from the New York State outcomes registries suggested that the apparent survival benefit of CABG over PCI in diabetic patients in the FREEDOM and SYNTAX trials (3, 4) might be lost when PCI was performed with EES (13); however, registries are particularly sensitive to the occurrence of selection bias, and these results must be interpreted with caution (14). Among the 554 diabetic patients randomized in EXCEL, a significant difference in mortality between CABG and PCI was observed in those with higher SYNTAX scores; however, EXCEL was not powered for mortality in the entire population, let alone the diabetic subgroup, and no interaction was noted between diabetic status, revascularization, and 3-year mortality. In a recently published pooled analysis of individual randomized patient data (15) from the SYNTAX, PRECOMBAT, EXCEL, and NOBLE trials (8, 16-18), there was no significant difference in 5-year mortality after treatment of 4478 patients with LMCAD with PCI versus CABG (10.7% versus 10.5%, HR 1.07, 95% CI 0.87-1.33; $p=0.52$), either in patients with (n=1120; HR 1.34, 95% CI 0.93-1.31) or without (n=3358; HR 0.94, 95% CI 0.72-1.23) diabetes. In this analysis CABG did, however, result in superior survival to PCI in diabetic patients with multivessel disease (but without LM involvement), again suggesting that in general patients with diabetes and complex CAD may preferentially benefit by CABG.

Finally, despite the fact that evidence supports the recommendation of increasing use of BIMA grafts during CABG in diabetic patients who are at low risk of deep sternal wound

infection (6, 19, 20), rates of BIMA usage are still relatively low (only 19.6% of diabetic patients in the present trial). No significant differences in sternal wound dehiscence were observed in diabetic patients treated with SIMA versus BIMA in EXCEL. It is also noteworthy that adherence rates to guideline-directed medication therapy after CABG have reached 90% in the EXCEL trial (21) but remain lower than after PCI. Of note, approximately one-third of CABG patients were discharged on DAPT, which while less than after PCI represents a higher percentage than in some other studies. This may reflect appropriate use after CABG in patients presenting with acute coronary syndromes, as well as the potential for DAPT to enhance graft patency (22), the topic of several ongoing RCTs (NCT02053909, NCT02352402, NCT01755520). Optimizing guideline-directed medication therapy after both CABG and PCI is essential for patients to derive the most benefits from revascularization.

Limitations. Although randomization was stratified by diabetes status and the diabetes subgroup analysis was pre-specified in the EXCEL trial design, the present study was not powered to detect a difference in the primary endpoint of death, stroke, or MI between PCI and CABG in the diabetic cohort, and secondary outcome measures were not adjusted for multiple comparisons. Hence, the results of the present study should be interpreted as hypothesis-generating only, and further investigation in dedicated trials of diabetic patients are warranted (23, 24). In addition, the EXCEL trial enrolled patients with LMCAD and site-assessed low or intermediate SYNTAX scores who were eligible to undergo both PCI and CABG. Therefore, these findings cannot be extrapolated either to patients with unacceptable high surgical risk or patients with coronary anatomy unsuitable for PCI. A major focus of diabetes management is optimal glycemic control. Recently, the use of gliflozins has been shown to reduce the risk of major cardiovascular events in patients with type 2 diabetes (25). Unfortunately, the use of

specific oral hypoglycemic agents and data on long-term glycemic control were not collected in the present study. Finally, follow-up in EXCEL is complete only through 3 years; longer-term surveillance is necessary to examine whether additional differences emerge over time.

Conclusions. In the large-scale EXCEL trial, among both diabetic and non-diabetic patients with LM disease and site-assessed low-to-intermediate (≤ 32) SYNTAX scores, PCI using EES and CABG resulted in similar rates of the primary composite endpoint of death, stroke, or MI at 3-year follow-up, although fewer adverse events at 30 days occurred after PCI. For diabetic patients with LM disease and relatively non-complex coronary anatomy, PCI may be a reasonable approach, whereas CABG should be considered for diabetic patients with more complex CAD.

Clinical Perspectives

Competency in Medical Knowledge: Over 3 years of follow-up, diabetic patients with left main coronary artery disease (LMCAD) undergoing myocardial revascularization are at substantially higher risk of mortality and major adverse events than LMCAD patients without diabetes. In the EXCEL trial there was no difference in the 3-year primary composite endpoint of all-cause death, stroke, or myocardial infarction between PCI and CABG irrespective of baseline diabetes status.

Competency in Patient Care: Before cardiac catheterization, diabetic patients should be informed about the importance of a ‘Heart Team’ approach of determining the most optimal treatment and procedural aspects of both PCI and CABG.

Translational Outlook: PCI may be a reasonable treatment strategy for diabetic patients with LMCAD and relatively non-complex coronary anatomy, whereas CABG should remain the standard of care for diabetic patients with more complex CAD.

REFERENCES

1. Roglic G. WHO Global report on diabetes: A summary. *International Journal of Noncommunicable Diseases*. 2016;1(1):3-8.
2. Kappetein AP, Head SJ. CABG or PCI for revascularisation in patients with diabetes? *Lancet Diabetes Endocrinol*. 2013;1(4):266-8.
3. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg*. 2013;43(5):1006-13.
4. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med*. 2012;367(25):2375-84.
5. Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. 2013;1(4):317-28.
6. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg*. 2014;46(4):517-92.
7. Cavalcante R, Sotomi Y, Mancone M, Whan Lee C, Ahn JM, Onuma Y, et al. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled

- analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. *Eur Heart J*. 2017;38(25):1969-77.
8. Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. *N Engl J Med*. 2016;375(23):2223-35.
 9. Kappetein AP, Serruys PW, Sabik JF, Leon MB, Taggart DP, Morice MC, et al. Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. *EuroIntervention*. 2016;12(7):861-72.
 10. Head SJ, Kaul S, Mack MJ, Serruys PW, Taggart DP, Holmes DR, Jr., et al. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. *Eur Heart J*. 2013;34(32):2510-8.
 11. Lee PH, Ahn JM, Chang M, Baek S, Yoon SH, Kang SJ, et al. Left Main Coronary Artery Disease: Secular Trends in Patient Characteristics, Treatments, and Outcomes. *J Am Coll Cardiol*. 2016;68(11):1233-46.
 12. Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farooq V, Tateishi H, et al. Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. *J Am Coll Cardiol*. 2016;68(10):999-1009.
 13. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease. *Circ Cardiovasc Interv*. 2015;8(7):e002626.
 14. Ferreira-Gonzalez I, Marsal JR, Mitjavila F, Parada A, Ribera A, Cascant P, et al. Patient registries of acute coronary syndrome: assessing or biasing the clinical real world data? *Circ Cardiovasc Qual Outcomes*. 2009;2(6):540-7.

15. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet*. 2018;391(10124):939-48.
16. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet*. 2013;381(9867):629-38.
17. Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, et al. Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. *J Am Coll Cardiol*. 2015;65(20):2198-206.
18. Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet*. 2016;388(10061):2743-52.
19. Aldea GS, Bakaeen FG, Pal J, Fremes S, Head SJ, Sabik J, et al. The Society of Thoracic Surgeons clinical practice guidelines on arterial conduits for coronary artery bypass grafting. *Ann Thorac Surg*. 2016;101(2):801-9.
20. Raza S, Sabik JF, 3rd, Masabni K, Ainkaran P, Lytle BW, Blackstone EH. Surgical revascularization techniques that minimize surgical risk and maximize late survival after coronary artery bypass grafting in patients with diabetes mellitus. *J Thorac Cardiovasc Surg*. 2014;148(4):1257-64; discussion 64-6.

21. Pinho-Gomes AC, Azevedo L, Ahn JM, Park SJ, Hamza TH, Farkouh ME, et al. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. *J Am Coll Cardiol*. 2018;71(6):591-602.
22. Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, et al. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. *Jama*. 2018;319(16):1677-86.
23. Head SJ, Kaul S, Tijssen JG, Serruys PW, Kappetein AP. Subgroup analyses in trial reports comparing percutaneous coronary intervention with coronary artery bypass surgery. *Jama*. 2013;310(19):2097-8.
24. Althouse AD. Adjust for Multiple Comparisons? It's Not That Simple. *Ann Thorac Surg*. 2016;101(5):1644-5.
25. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondy N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017;377(7):644-57.

FIGURE LEGENDS

Central Illustration. Impact of diabetes mellitus on 3-year outcomes after left main revascularization. The incidence rates of the primary composite endpoint of death, stroke, or MI among diabetic and non-diabetic patients (A) and according to the type of revascularization procedure (B) are shown. Over the 3-year follow-up period, PCI with EES compared with CABG was associated with similar risk of the primary composite endpoint among both diabetic and non-diabetic patients. CABG = coronary artery bypass grafting, CI = confidence interval, DM = diabetes mellitus, EES = everolimus-eluting stents, HR = hazard ratio, MI = myocardial infarction, PCI = percutaneous coronary intervention.

Figure 1. Three-Year Outcomes of PCI Versus CABG in Diabetic and Nondiabetic Patients

Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial infarction (MI); the composite endpoint of all-cause death, stroke, MI, or ischemia-driven repeat revascularization (IDR); all-cause death; and IDR in patients with (A-D) and without (E-H) diabetes. P-values are from log-rank test. CABG = coronary artery bypass grafting; CI = confidence interval; HR = hazard ratio; PCI = percutaneous coronary intervention.

Figure 2. Three-Year Outcomes in Patients with Diabetes Stratified by Insulin Treatment

Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial infarction (MI) among non-insulin treated (A) and insulin-treated (B) patients. P-values are from log-rank test. CABG = coronary artery bypass grafting; CI = confidence interval; HR = hazard ratio; PCI = percutaneous coronary intervention.

Figure 3. Three-Year Outcomes for Diabetic and Nondiabetic Patients According to Anatomic Lesion Complexity as Measured by the Site-Assessed SYNTAX Score

Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial infarction (MI); the composite endpoint of all-cause death, stroke, MI, or ischemia-driven repeat revascularization (IDR); all-cause death; and IDR in diabetic patients (A-D) and non-diabetic patients (E-H). Treatment by SYNTAX score interactions in the diabetic and the non-diabetic groups: The composite endpoint of all-cause death, stroke, or MI ($p_{\text{int}}=0.81$ and $p_{\text{int}}=0.98$); the composite endpoint of all-cause death, stroke, MI, or IDR ($p_{\text{int}}=0.87$ and $p_{\text{int}}=0.31$); all-cause death ($p_{\text{int}}=0.32$ and $p_{\text{int}}=0.40$); and IDR ($p_{\text{int}}=0.63$ and $p_{\text{int}}=0.10$). P values are from log-rank test. Rates are separated according to the site-reported SYNTAX score values, indicating low (0–22) and intermediate (23–32) anatomic lesion complexity. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; IDR = ischemia-driven revascularization.

Table 1. Baseline Characteristics of Patients According to Diabetes Status in the Overall Cohort

	<i>No Diabetes (n = 1350)</i>	<i>Diabetes (n = 554)</i>	<i>p Value</i>
Age, years	65.7 ± 9.7	66.5 ± 9.2	0.17
Male sex	78.0 (1053/1350)	74.0 (410/554)	0.06
Body mass index, kg/m ²	28.0 ± 4.5	30.4 ± 5.5	<0.001
Hyperlipidemia treated with medication	65.7 (886/1348)	80.5 (445/553)	<0.001
Hypertension treated with medication	68.2 (921/1350)	87.5 (485/554)	<0.001
Current smoker	23.9 (321/1343)	17.3 (95/548)	0.002
Prior myocardial infarction	17.1 (229/1339)	18.4 (101/549)	0.50
Congestive heart failure	5.7 (77/1345)	8.9 (49/553)	0.01
History of carotid artery disease	7.3 (98/1345)	10.5% (58/551)	0.02
Prior stroke	3.0 (41/1349)	5.1 (28/554)	0.03
Prior transient ischemic attack	2.8 (38/1343)	3.5 (19/550)	0.47
Peripheral vascular disease	7.7 (103/1344)	14.1 (78/552)	<0.001
Chronic kidney disease*	14.5 (191/1320)	21.3 (117/549)	<0.001
Anemia†	20.1 (268/1334)	36.1 (200/554)	<0.001
Recent myocardial infarction (within 7 days)	15.1 (203/1345)	14.3 (79/552)	0.66
Unstable angina without recent myocardial infarction	23.1 (311/1345)	27.7 (153/552)	0.03
Prior percutaneous coronary intervention	15.3 (206/1348)	21.7 (120/554)	<0.001
Left ventricular ejection fraction, %	57.4 ± 9.1	56.6 ± 9.8	0.19
Society of Thoracic Surgeons score	0.85 ± 0.81	0.96 ± 0.91	0.01
SYNTAX score			
Site-assessed	20.5 ± 6.3	20.8 ± 5.9	0.25
0-22	61.8 (833/1348)	57.1 (316/553)	0.060
23-32	38.2 (515/1348)	42.9 (237/553)	0.060
≥33	0 (0/1348)	0 (0/553)	—
Core laboratory assessed	26.2 ± 9.4	27.3 ± 9.1	0.02
0-22	37.7 (491/1302)	31.1 (167/537)	0.007
23-32	38.6 (502/1302)	43.6 (234/537)	0.047
≥33	23.7 (309/1302)	25.3 (136/537)	0.47
Coronary anatomy, core laboratory-assessed			
Left main distal bifurcation involvement	56.3 (568/1009)	62.6 (253/404)	0.03

Number of lesions treated per patient	2.2 ± 0.9	2.3 ± 0.9	0.02
Number of treated non-left main diseased vessels	1.5 ± 1.0	1.7 ± 1.0	<0.001
0	18.8 (250/1328)	14.6 (80/549)	0.03
1	32.8 (435/1328)	27.1 (149/549)	0.02
2	31.3 (416/1328)	37.2 (204/549)	0.01
3	17.1 (227/1328)	21.1 (116/549)	0.04
Diffuse disease or small vessels	4.7 (62/1321)	9.3 (51/549)	<0.001

Values are mean ± standard deviation or % (n/N). *Estimated glomerular filtration rate <60 mL/min; †hemoglobin <12 g/dL in women and <13 g/dL in men.

Table 2. Procedural Characteristics and Discharge Medications According to Diabetes Status and Revascularization Assignment

	<i>CABG (n = 956)</i>			<i>PCI (n = 948)</i>		
	No diabetes (n = 688)	Diabetes (n = 268)	p Value	No diabetes (n = 662)	Diabetes (n = 286)	p Value
Procedural characteristics						
Assigned procedure performed	97.0 (667/688)	95.5 (256/268)	0.28	98.6 (653/662)	98.6 (282/286)	0.96
Time to procedure, days	6.8 ± 15.1	6.5 ± 11.9	0.69	3.4 ± 5.7	3.0 ± 4.1	0.73
Procedure duration, minutes	241.9 ± 70.9	246.2 ± 69.2	0.37	80.2 ± 41.8	87.7 ± 41.8	0.005
Off-pump CABG	30.1 (201/667)	27.3 (70/256)	0.40	—	—	—
Bypass time, minutes	81.6 ± 42.4	87.4 ± 51.0	0.21	—	—	—
Any internal mammary artery used	99.1 (658/664)	98.0 (250/255)	0.19	—	—	—
Both internal mammary arteries used	32.4 (215/664)	19.6 (50/255)	<0.001	—	—	—
No. of grafts	2.5 ± 0.8	2.6 ± 0.8	0.50	—	—	—
No. of stents implanted	—	—	—	2.4 ± 1.5	2.6 ± 1.5	0.08
Total stent length, mm	—	—	—	48.0 ± 35.4	51.7 ± 36.4	0.09
Distal LM bifurcation treated	—	—	—	56.7 (366/645)	58.2 (163/280)	0.68
2-stent approach	—	—	—	33.1 (121/366)	39.3 (64/163)	0.17
Crush or mini-crush	—	—	—	10.3 (12/117)	21.9 (14/64)	0.03
FFR used	—	—	—	9.0 (59/653)	8.9 (25/281)	0.95
IVUS used	—	—	—	77.3 (505/653)	77.0 (217/282)	0.90
Duration of hospital stay, days	12.5 ± 9.5	13.2 ± 9.9	0.66	5.4 ± 5.3	5.5 ± 5.1	0.33
Discharge medications						
Aspirin	98.9 (651/658)	98.8 (245/248)	>0.99	98.9 (641/648)	99.3 (278/280)	0.73
P2Y12 inhibitor	33.7 (223/661)	30.4 (76/250)	0.34	98.3 (639/650)	97.2 (273/281)	0.25
DAPT	33.4 (221/661)	28.8 (72/250)	0.18	97.4 (633/650)	96.1 (270/281)	0.29
Statin	92.6 (612/661)	92.0 (230/250)	0.77	96.0 (624/650)	97.5 (274/281)	0.25
Beta-blocker	92.7 (613/661)	92.0 (230/250)	0.71	83.1 (540/650)	83.6 (235/281)	0.84
ACEI or ARB	40.7 (269/661)	46.0 (115/250)	0.15	54.8 (154/281)	57.5 (374/650)	0.44

Values are mean ± standard deviation or % (n/N). ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; CABG = coronary artery bypass grafting; DAPT = dual antiplatelet therapy; LM = left main coronary artery; PCI = percutaneous coronary intervention.

Table 3. Thirty-Day Clinical Outcomes According to Diabetes Status and Revascularization Assignment


	<i>All (n=1904)</i>			<i>No Diabetes (n=1350)</i>			<i>Diabetes (n=554)</i>			P_{interaction}
	No diabetes (n = 1350)	Diabetes (n = 554)	p Value	CABG (n = 688)	PCI (n = 662)	p Value	CABG (n = 268)	PCI (n = 286)	p Value	
Death, stroke, or MI	6.0 (80)	7.5 (41)	0.24	7.2 (49)	4.7 (31)	0.06	9.8 (26)	5.3 (15)	0.05	0.61
Death, stroke, MI, or IDR	6.3 (84)	7.6 (42)	0.29	7.8 (53)	4.7 (31)	0.02	10.2 (27)	5.3 (15)	0.03	0.69
Death	0.9 (12)	1.3 (7)	0.46	0.9 (6)	0.9 (6)	0.96	1.5 (4)	1.1 (3)	0.63	0.68
Cardiovascular	0.8 (11)	1.3 (7)	0.36	0.7 (5)	0.9 (6)	0.73	1.5 (4)	1.1 (3)	0.63	0.58
Stroke	0.8 (10)	1.5 (8)	0.15	0.9 (6)	0.6 (4)	0.55	2.3 (6)	0.7 (2)	0.13	0.44
MI	4.9 (66)	5.5 (30)	0.65	6.1 (41)	3.8 (25)	0.06	6.8 (18)	4.2 (12)	0.20	0.98
Periprocedural	4.9 (65)	4.6 (25)	0.77	5.9 (40)	3.8 (25)	0.08	6.1 (16)	3.2 (9)	0.12	0.68
Spontaneous	0.1 (1)	0.9 (5)	0.003	0.1 (1)	0	0.32	0.8 (2)	1.1 (3)	0.72	0.99
All repeat revascularization	1.0 (13)	1.3 (7)	0.56	1.3 (9)	0.6 (4)	0.18	1.5 (4)	1.1 (3)	0.63	0.66
IDR	0.9 (12)	1.3 (7)	0.46	1.3 (9)	0.5 (3)	0.09	1.5 (4)	1.1 (3)	0.63	0.48
PCI	0.5 (7)	1.3 (7)	0.09	0.6 (4)	0.5 (3)	0.74	1.5 (4)	1.1 (3)	0.63	0.92
CABG	0.4 (5)	0	0.15	0.7 (5)	0	0.03	0	0	—	>0.99
Graft occlusion or stent thrombosis	0.7 (9)	0.9 (5)	0.59	1.2 (8)	0.2 (1)	0.02	1.1 (3)	0.7 (2)	0.59	0.26
Major adverse events*	15.3 (204)	15.1 (83)	0.92	23.1 (156)	7.3 (48)	<0.001	23.5 (62)	7.4 (21)	<0.001	0.97

Data are Kaplan-Meier time-to-first event estimates expressed as % (n). *The composite rate of death, stroke, myocardial infarction, TIMI major or minor bleeding, transfusion ≥ 2 units of blood, major arrhythmia (supraventricular tachycardia requiring cardioversion, ventricular tachycardia or fibrillation requiring treatment, or bradyarrhythmia requiring temporary or permanent pacemaker), ischemia-driven revascularization, any unplanned surgery or therapeutic radiologic procedure, renal failure (serum creatinine increase by ≥ 0.5 mg/dL from baseline or need for dialysis), sternal wound dehiscence, infection requiring antibiotics, or prolonged intubation (>48 hours). CABG = coronary artery bypass grafting; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention.

Table 4. Three-Year Clinical Outcomes According to Diabetes Status and Revascularization Assignment


	<i>All (N = 1904)</i>			<i>No diabetes (n = 1350)</i>			<i>Diabetes (n = 554)</i>			
	No Diabetes (n = 1350)	Diabetes (n = 554)	p Value	CABG (n = 688)	PCI (n = 662)	p Value	CABG (n = 268)	PCI (n = 286)	p Value	P_{interaction}
Death, stroke, or MI	12.9 (170)	20.0 (109)	<0.001	12.9 (86)	12.9 (84)	0.89	19.3 (51)	20.7 (58)	0.87	0.82
Death, stroke, MI, or IDR	18.9 (248)	26.1 (142)	<0.001	17.5 (116)	20.2 (132)	0.28	22.8 (60)	29.2 (82)	0.17	0.65
Death	5.3 (69)	10.9 (59)	<0.001	5.0 (33)	5.5 (36)	0.71	8.0 (21)	13.6 (38)	0.046	0.22
Cardiovascular	3.1 (41)	6.2 (33)	0.002	3.1 (20)	3.2 (21)	0.85	5.4 (14)	7.0 (19)	0.48	0.68
Stroke	2.3 (30)	3.6 (19)	0.11	2.3 (15)	2.3 (15)	0.99	5.1 (13)	2.3 (6)	0.08	0.17
MI	7.3 (96)	10.5 (56)	0.03	7.5 (50)	7.1 (46)	0.73	10.8 (28)	10.3 (28)	0.76	0.99
Periprocedural	5.0 (67)	4.7 (26)	0.80	6.1 (41)	4.0 (26)	0.09	6.1 (16)	3.5 (10)	0.17	0.81
Spontaneous	2.4 (30)	6.4 (33)	<0.001	1.6 (10)	3.2 (20)	0.06	5.6 (14)	7.2 (19)	0.50	0.38
All repeat revascularization	9.2 (117)	13.1 (68)	0.01	7.0 (45)	11.3 (72)	0.008	9.1 (23)	16.9 (45)	0.01	0.68
IDR	9.0 (115)	12.9 (67)	0.01	7.0 (45)	11.0 (70)	0.01	8.7 (22)	16.9 (45)	0.008	0.51
PCI	7.6 (97)	11.1 (58)	0.01	6.1 (39)	9.1 (58)	0.04	8.3 (21)	13.8 (37)	0.058	0.77
CABG	2.0 (26)	2.2 (11)	0.89	0.9 (6)	3.1 (20)	0.005	0.4 (1)	3.8 (10)	0.009	0.37
Graft occlusion or stent	2.6 (34)	4.0 (21)	0.12	4.8 (31)	0.5 (3)	<0.001	6.7 (17)	1.5 (4)	0.002	0.32

Values are Kaplan-Meier time-to-first event estimates expressed as % (n). CABG = coronary artery bypass grafting; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention.




Number at risk:

PCI	286	262	253	240	226	220	213
CABG	268	225	223	218	214	209	205




Number at risk:

PCI	286	256	239	223	207	198	192
CABG	268	222	218	212	205	202	199




Number at risk:


PCI	286	275	266	255	244	238	230
CABG	268	252	248	243	240	238	234




Number at risk:


PCI	286	264	247	230	215	204	199
CABG	268	244	236	229	222	222	218






662	605	574	551	537	521	498
688	594	576	560	550	527	509









Number at risk:


PCI	213	200	193	184	173	169	166
CABG	194	167	165	160	157	153	149



■ PCI


■ CABG





Number at risk:

DM	554	487	476	458	440	429	418
Non-DM	1350	1218	1194	1168	1152	1127	1080



Number at risk:

PCI: DM	286	262	253	240	226	220	213
CABG: DM	268	225	223	218	214	209	205
PCI: Non-DM	662	612	601	590	580	572	544
CABG: Non-DM	688	606	593	578	572	555	536